Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei (PMP) is associated with excessive bleeding and acquired fibrinogen deficiency. Maintaining plasma fibrinogen may support hemostasis. Objectives: To compare hemostatic efficacy and safety of human fibrinogen concentrate (HFC) vs cryoprecipitate as fibrinogen sources for bleeding patients with acquired fibrinogen deficiency undergoing PMP CRS. Methods: FORMA-05 was an off-label single-center, prospective, randomized, controlled phase 2 study. Patients undergoing PMP surgery with predicted intraoperative blood loss ≥2 L received human fibrinogen concentrate (HFC; 4 g) or cryoprecipitate (two pools of 5 units, containing approximat...
BACKGROUND Cardiac surgery with cardiopulmonary bypass impairs hemostasis due to hemodilution and co...
BACKGROUND AND OBJECTIVES: Treatment of dilutional coagulopathy by transfusing fresh frozen plasma (...
[Introduction]: Massive hemorrhage continues to be a treatable cause of death. Its management varies...
Importance: Fibrinogen concentrate might partly restore coagulation defects and reduce intraoperativ...
WOS: 000424395000021PubMed ID: 29194665BACKGROUNDFibrinogen concentrate is the preferred choice for ...
ObjectivesWe assessed whether fibrinogen concentrate as targeted first-line hemostatic therapy was m...
The consumption of fibrinogen concentrates has been increasing steadily for several years in surgery...
Excessive bleeding is one of the most common complications in cardiac surgery and is caused most fre...
There is great variation in the study design of the 21 major randomized controlled trials assessing ...
This study aims to assess the efficacy and safety of fibrinogen concentrate in acquired hypofibrinog...
Background: Contact of blood with the cardiopulmonary bypass (CPB) circuit during cardiac surgery in...
Background: Single-dose human fibrinogen concentrate (FCH) might have haemostatic benefits in comple...
BACKGROUND: Hypofibrinogenaemia is one of the main reasons for development of perioperative coagulop...
The use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates (FIBCs) to achieve he...
Background: Studies evaluating the hemostatic effects of fibrinogen administration in cardiac surger...
BACKGROUND Cardiac surgery with cardiopulmonary bypass impairs hemostasis due to hemodilution and co...
BACKGROUND AND OBJECTIVES: Treatment of dilutional coagulopathy by transfusing fresh frozen plasma (...
[Introduction]: Massive hemorrhage continues to be a treatable cause of death. Its management varies...
Importance: Fibrinogen concentrate might partly restore coagulation defects and reduce intraoperativ...
WOS: 000424395000021PubMed ID: 29194665BACKGROUNDFibrinogen concentrate is the preferred choice for ...
ObjectivesWe assessed whether fibrinogen concentrate as targeted first-line hemostatic therapy was m...
The consumption of fibrinogen concentrates has been increasing steadily for several years in surgery...
Excessive bleeding is one of the most common complications in cardiac surgery and is caused most fre...
There is great variation in the study design of the 21 major randomized controlled trials assessing ...
This study aims to assess the efficacy and safety of fibrinogen concentrate in acquired hypofibrinog...
Background: Contact of blood with the cardiopulmonary bypass (CPB) circuit during cardiac surgery in...
Background: Single-dose human fibrinogen concentrate (FCH) might have haemostatic benefits in comple...
BACKGROUND: Hypofibrinogenaemia is one of the main reasons for development of perioperative coagulop...
The use of prothrombin complex concentrates (PCCs) and fibrinogen concentrates (FIBCs) to achieve he...
Background: Studies evaluating the hemostatic effects of fibrinogen administration in cardiac surger...
BACKGROUND Cardiac surgery with cardiopulmonary bypass impairs hemostasis due to hemodilution and co...
BACKGROUND AND OBJECTIVES: Treatment of dilutional coagulopathy by transfusing fresh frozen plasma (...
[Introduction]: Massive hemorrhage continues to be a treatable cause of death. Its management varies...